Accurate, balanced evidence-based information about medicines
Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDFNPS RADAR April 2008 NPS RADAR April 2008
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR April 2008 NPS RADAR>Full Issue>Health Professional Publication | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Methylphenidate (Ritalin LA): a second controlled-release formulation PBS listed for attention deficit hyperactivity disorder NPS RADAR>Brief Item>Health Professional Publication | A second controlled-release formulation of methylphenidate (Ritalin LA) was listed on the PBS to be prescribed for patients aged 6 to 18 years inclusive for attention deficit hyperactivity disorder (ADHD). |
| Smaller dose volume of influenza vaccine PBS listed for children aged 6-35 months NPS RADAR>Brief Item>Health Professional Publication | A smaller dose volume (0.25 mL) of influenza vaccine has been PBS listed for children aged 6-35 months who are at risk of adverse outcomes from lower respiratory tract infections. |
| Terbinafine authority listed for fungal infections in Aboriginal and Torres Strait Islander peoples NPS RADAR>Brief Item>Health Professional Publication | The authority listing for terbinafine 250 mg tablets was extended o allow the treatment of Aboriginal and Torres Strait Islander peoples with a dermatophyte infection that has not responded to topical treatment. |
| Pioglitazone (Actos) for type 2 diabetes mellitus NPS RADAR>Review>Health Professional Publication | Information on use of pioglitazone (Actos) for type 2 diabetes mellitus, including safety and dosing issues. |
| Fentanyl lozenges (Actiq) for breakthrough cancer pain NPS RADAR>Review>Health Professional Publication | Information on use of fentanyl lozenges (Actiq) for breakthrough cancer pain, including safety concerns and dosing issues. |
| Paliperidone (Invega) for schizophrenia NPS RADAR>Review>Health Professional Publication | Information on use of paliperidone (Invega) for schizophrenia, including safety and dosing issues. |
| Intolerance and contraindications to metformin NPS RADAR>Web Only Item>Health Professional Publication | Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidosis, and renal impairment. |
| New York Heart Association grading of heart failure (NYHA) NPS RADAR>Web Only Item>Health Professional Publication | Provides New York Heart Association grading of heart failure (NYHA) as additional content to pioglitazone use for type 2 diabetes mellitus. |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2008-04-01 00:00:00
The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of clinical circumstances of each patient.
RSS feed
